To assess its therapeutic potential, VUTI was tested in an amylin diet-induced obese (AMLN-DIO) Non-Alcoholic SteatoHepatitis (NASH) mouse model, which exhibits severe liver steatosis and inflammation. This evidence concerns the gene IAPP and metabolic dysfunction-associated steatohepatitis.